Clinical trials: Allogenic Disease
Bone Tumors
Bioactive Glass Granules in Filling of Bone Defects
This is a randomized clinical trial that will be carried out to examine the use of bioactive glass granules (S53P4) as bone graft substitute in filling small and large bone defects as compared with autogenous and allogeneic bone…
- Trial name
- NCT01304121
- Testing
- Bioactive glass (SP53P4)
- Where
- Finland
- Volunteers
- 48 people
- Sponsor
- Turku University Hospital
Coronary Artery Disease, Coronary Artery Bypass
Impact of Fluid Restriction Policy in Reducing the Use of Red Cells in Cardiac Surgery
The investigators' hypothesis is that restriction of circulating fluids in comparison to a liberal fluid administration policy would lead to a reduction of allogenic red blood cells exposure in patients undergoing cardiopulmonary…
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass, Erythrocyte Transfusion
- Trial name
- NCT00600704
- Testing
- Fluid Restriction Policy, Free fluid infusion
- Where
- Greece
- Volunteers
- 192 people
- Sponsor
- Larissa University Hospital
HSCT, EBV Infection
Zuberitamab for EBV Infection Post-Allo-HSCT
EBV DNAemia is defined as the presence of EBV-DNA load in peripheral blood exceeding the normal threshold, serving as a key diagnostic indicator for EBV-associated post-transplant lymphoproliferative disorder (EBV-PTLD).
- Trial name
- NCT07261215
- Testing
- Zuberitamab
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT06551584
- Testing
- ORCA-T
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Stanford University
Venous Leg Ulcer
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)
The aim of this clinical trial is to investigate the efficacy and safety of allo-APZ2-CVU, administered topically on therapy-resistant non-healing CVUs compared to placebo.
- Trial name
- NCT06489028
- Testing
- allo-APZ2-CVU
- Where
- 15 sites in United States, Austria and 10 more
- Volunteers
- 250 people
- Sponsor
- RHEACELL GmbH & Co. KG
Liver Cirrhosis
Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Cirrhosis
The objective of this study is to evaluate the therapeutic efficacy of allogenic bone marrow stem cells (BMSCs) transplantation in patients with liver cirrhosis.
- Trial name
- NCT01223664
- Testing
- Allogenic bone marrow stem cells transplantation, Conserved therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Gastrointestinal Mucositis, Malignant Neoplasm
Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant
This randomized phase II trial is studying palifermin to see how well it works compared with a placebo in preventing oral mucositis caused by chemotherapy and/or radiation therapy in young patients undergoing stem cell…
- Trial name
- NCT00728585
- Testing
- Palifermin
- Sponsor
- Children's Oncology Group
Leukemia, Erythroblastic, Acute, Myelodysplastic Syndromes
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
The purpose of this study is to determine whether 5-Azacytidine priming before the conditioning regimen for subjects receiving a hematopoietic stem cell transplant is an effective treatment for high risk myeloid malignancies in…
- Trial name
- NCT02497404
- Testing
- 5-Azacytidine, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Weill Medical College of Cornell University
Breast Cancer, Ovarian Cancer
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05239143
- Testing
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Where
- 14 sites in United States
- Volunteers
- 180 people
- Sponsor
- Poseida Therapeutics, Inc.
Ovarian Cancer, Fallopian Tube Carcinoma
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
This is a single center phase I trial designed to determine the maximum tolerated dose (MTD) of the oral IDO inhibitor INCB024360 when administered as part of a larger regimen of intraperitoneal (IP) delivery of haploidentical…
- Conditions
- Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT02118285
- Testing
- Fludarabine, Cyclophosphamide, NK cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Periapical Periodontitis
Encapsulated Mesenchymal Stem Cells for Dental Pulp Regeneration.
To compare the dental survival in a period of one year of mature permanent teeth with apical lesion following the administration of encapsulated Mesenchymal Stem Cells under a regenerative endodontic procedure and a conventional…
- Trial name
- RanoKure (NCT03102879)
- Testing
- Regenerative Endodontic Procedure, Conventional Root Canal Treatment
- Where
- Chile
- Volunteers
- 36 people
- Sponsor
- Universidad de los Andes, Chile
Relapsed or Refractory Multiple Myeloma
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the…
- Trial name
- NCT07681596
- Testing
- AZD4045, Daratumumab, Aldesleukin
- Where
- 12 sites in United States, Australia
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Cytomegalovirus Infections, Infection Reactivation
ATG Individualized Dosing Model in URD-PBSCT.
Anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation to prevent severe graft-versus-host disease (GVHD) and graft failure.
- Conditions
- Cytomegalovirus Infections, Infection Reactivation, Stem Cell Transplant Complications
- Trial name
- NCT06572462
- Testing
- individualized ATG dosing strategy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Acute Graft Versus Host Disease
Clinical Trial With MSC for Graft Versus Host Disease Treatment
Sequential administration of MSCs obtained from adipose tissue is an effective and safe treatment for acute graft versus host disease refractory to first-line treatment.
- Trial name
- NCT02687646
- Testing
- Adult Allogeneic Mesenchymal cells from adipose tissue.
- Where
- 6 sites in Spain
- Volunteers
- 16 people
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Hematologic Malignancies
Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC)
Prospective randomized study of allogeneic minitransplantation from HLA-identical family or unrelated donors comparing unmanipulated or CD8-depleted PBSC.
- Trial name
- NCT00693927
- Testing
- Unmanipulated PBSC after nonmyeloablative conditioning, CD8-depleted PBSC after nonmyeloablative conditioning
- Where
- Belgium
- Volunteers
- 54 people
- Sponsor
- University of Liege
Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
This phase I/II trial studies the safety, side effects, and best dose of decitabine in combination with fludarabine, cytarabine, filgrastim, and idarubicin (FLAG-Ida) and total body irradiation (TBI) followed by a donor stem cell…
- Conditions
- Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT06928662
- Testing
- Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
This is a continuation of a pilot study which is now regarded as a phase II trial with a plan to enroll an additional 40 patients (20 related and 20 unrelated donor transplants) with hematological malignancy assessing the safety…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00571662
- Testing
- Pentostatin, Total-body irradiation (TBI), Cyclosporine A (CsA)
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of Nebraska
Non-Neoplastic Hematologic and Lymphocytic Disorder
Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
This phase II clinical trial studies how well treosulfan and fludarabine phosphate with or without low dose radiation before donor stem cell transplantation works in treating patients with nonmalignant (noncancerous) diseases.
- Trial name
- NCT00919503
- Testing
- Allogeneic Bone Marrow Transplantation, Anti-Thymocyte Globulin, Cyclosporine
- Where
- 6 sites in United States
- Volunteers
- 98 people
- Sponsor
- Fred Hutchinson Cancer Center
Stem Cell Transplantation, Graft Vs Host Disease
Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation
Allogeneic stem cell transplantation is the treatment of choice for a growing number of malignant and non-malignant indications.
- Trial name
- NCT00130754
- Testing
- Thymoglobuline
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Hadassah Medical Organization
Acute Myeloid Leukemia, Myelodysplastic Syndromes
IFN-α in Relapse Prevention.
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry…
- Trial name
- NCT07449286
- Testing
- IFN-α
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.